Cargando…

QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease

Parkinson’s disease is one of the most common neurodegenerative illnesses in older persons and the leucine-rich repeat kinase 2 (LRRK2) is an auspicious target for its pharmacological treatment. In this work, quantitative structure–activity relationship (QSAR) models for identification of putative i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sebastián-Pérez, Víctor, Martínez, María Jimena, Gil, Carmen, Campillo, Nuria Eugenia, Martínez, Ana, Ponzoni, Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2019
Materias:	Workshops
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798859/ https://www.ncbi.nlm.nih.gov/pubmed/30763264 http://dx.doi.org/10.1515/jib-2018-0063

Ejemplares similares

QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer’s Disease
por: Ponzoni, Ignacio, et al.
Publicado: (2019)

Hybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery
por: Ponzoni, Ignacio, et al.
Publicado: (2017)

MoDeSuS: A Machine Learning Tool for Selection of Molecular Descriptors in QSAR Studies Applied to Molecular Informatics
por: Martínez, María Jimena, et al.
Publicado: (2019)

Visual analytics in cheminformatics: user-supervised descriptor selection for QSAR methods
por: Martínez, María Jimena, et al.
Publicado: (2015)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

Design of optical baffles and their integration in beampipes
por: Martinez-Perez, Mario
Publicado: (2023)

Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3
por: Sebastián-Pérez, Victor, et al.
Publicado: (2022)

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
por: Bright, Jessica M., et al.
Publicado: (2021)

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
por: Deng, Xianming, et al.
Publicado: (2011)

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson’s disease
por: Martínez, Martín, et al.
Publicado: (2023)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s Disease in the Last Decade
por: Thakur, Gunjan, et al.
Publicado: (2022)

Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
por: Purlyte, Elena, et al.
Publicado: (2017)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease
por: Podlesniy, Petar, et al.
Publicado: (2019)

Materials and their production processing for ET's beampipes
por: Perez Fontenla, Ana Teresa
Publicado: (2023)

Hands-on: prepare data model on your Invenio 2 instance
por: WITOWSKI, Sebastian
Publicado: (2015)

Progress in LRRK2-Associated Parkinson’s Disease Animal Models
por: Seegobin, Steven P., et al.
Publicado: (2020)

Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction
por: Deniston, CK, et al.
Publicado: (2020)

Discovering NDM-1 inhibitors using molecular substructure embeddings representations
por: Papastergiou, Thomas, et al.
Publicado: (2023)

Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures
por: Sanz Murillo, Marta, et al.
Publicado: (2023)

2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors
por: Zhao, Manman, et al.
Publicado: (2017)

Proteome wide association studies of LRRK2 variants identify novel causal and druggable proteins for Parkinson’s disease
por: Phillips, Bridget, et al.
Publicado: (2023)

LRRK2 in Parkinson's disease and dementia with Lewy bodies
por: Zhu, Xiongwei, et al.
Publicado: (2006)

Metabolomic Profiling in LRRK2-Related Parkinson's Disease
por: Johansen, Krisztina K., et al.
Publicado: (2009)

Genetic Variants of LRRK2 in Taiwanese Parkinson’s Disease
por: Wu, Yih-Ru, et al.
Publicado: (2013)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
por: Bliederhaeuser, Corinna, et al.
Publicado: (2016)

Roco Proteins and the Parkinson’s Disease-Associated LRRK2
por: Liao, Jingling, et al.
Publicado: (2018)

LRRK2 and membrane trafficking: nexus of Parkinson’s disease
por: Hur, Eun-Mi, et al.
Publicado: (2019)

Parkinson's disease and mitophagy: an emerging role for LRRK2
por: Singh, Francois, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vsuakhe8cv4fsgbq8roc05uam3